Citadel Advisors
DMRA

Citadel Advisors’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Citadel Advisors’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4
Closed -$47 – 14580
2024
Q2 		$47 Sell
4
-4
-50% -$63 ﹤0.01% 14114
2024
Q1 		$156 Buy
+8
New +$142 ﹤0.01% 14407
2023
Q3 		– Sell
-112
Closed -$7.06K – 14590
2023
Q2 		$7.06K Buy
112
+72
+180% +$3.92K ﹤0.01% 13390
2023
Q1 		$1.99K Buy
+40
New +$2.11K ﹤0.01% 14225

Other funds holding DMRA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Citadel Advisors's DMRA Position: Q3 2024 in Review

Citadel Advisors sold out of Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q3 2024, closing a stake of 5,143 shares — an estimated $61K sold.

Citadel Advisors first reported a position in DMRA in Q1 2023 and held it in 5 quarters. The position peaked at $72.9K in Q1 2024. 10 funds tracked by Wall St. Rank hold DMRA as of Q3 2024.

  • Citadel Advisors reported no remaining Damora Therapeutics, Inc. Ordinary Shares position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 5,143 Damora Therapeutics, Inc. Ordinary Shares shares in Q3 2024, an estimated $61K.
  • Citadel Advisors first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q1 2023 and held it in 5 quarters.
  • Citadel Advisors's Damora Therapeutics, Inc. Ordinary Shares position peaked at $72.9K in Q1 2024.
  • 10 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.